Skip to main content
驱动力 logo

驱动力 — Investor Relations & Filings

Ticker · 920275 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 479 across all filing types
Latest filing 2022-06-29 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920275

About 驱动力

https://www.chinaedrive.com/

Drive Power Bio-tech specializes in the research, development, and manufacturing of functional additives designed for animal nutrition. The company focuses on hematopoietic technology, providing solutions that enhance hemoglobin synthesis, strengthen immune responses, and support intestinal health. Its product portfolio includes specialized nutritional supplements that optimize metabolic processes and improve growth performance. By leveraging biotechnological innovation, the company develops high-efficiency additives aimed at enhancing physiological health and production efficiency in large-scale agricultural environments.

Recent filings

Filing Released Lang Actions
关于公司收到政府上市补贴资金的公告
Capital/Financing Update Classification · 90% confidence The document is a short announcement (462 characters) regarding the receipt of a government subsidy by the company. It references accounting treatment according to accounting standards but does not contain any financial statements or detailed financial data. It is not a full report but a regulatory announcement about a financing-related event (government subsidy). The document is not a report publication announcement since it contains substantive information about the subsidy and its accounting treatment. Therefore, it fits best under Capital/Financing Update (CAP).
2022-06-29 Chinese
关于2022年股权激励计划股票期权授予结果的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of stock option grant registration for a company, including details about the number of options granted, exercise price, recipients, and performance conditions. It references regulatory rules from the China Securities Regulatory Commission and related stock exchange rules. The document does not contain financial statements or detailed financial performance data but rather discloses the stock option grant results and related terms. It is a regulatory announcement about a capital-related event (stock option grant) rather than a full financial report or management discussion. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 4323 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report. Hence, the classification is CAP with high confidence.
2022-06-26 Chinese
关于调整2022年股权激励计划相关事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangdong Driving Force Biotechnology Co., Ltd. regarding adjustments to its 2022 equity incentive plan, specifically changes to the exercise price and the number of stock options granted. It references board and supervisory meetings, independent director opinions, and legal opinions related to the equity incentive plan. The document is a formal announcement of changes to a stock option plan, which is a capital structure related update. It does not contain financial statements or detailed financial performance data, nor is it a full report or earnings release. The document is not a report publication announcement since it contains substantive content about the adjustment. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3438 characters, which is consistent with an announcement rather than a full report.
2022-06-07 Chinese
2022年股权激励计划激励对象名单
Director's Dealing Classification · 95% confidence The document is a company announcement listing the allocation of stock options or equity incentives to executives and core employees, including detailed tables of recipients and their respective shares. It includes names, positions, and quantities of stock options granted. The document is relatively short (1019 characters) and focuses on equity incentive distribution rather than financial results, management changes, or voting outcomes. This type of announcement typically falls under disclosures related to share-based compensation or insider dealings. Given the content, it aligns best with Director's Dealing (DIRS), which covers reports of personal share transactions or equity incentives granted to directors and executives. There is no indication of a full financial report, meeting materials, or voting results. Therefore, the classification is DIRS with high confidence.
2022-06-07 Chinese
华安证券股份有限公司关于广东驱动力生物科技股份有限公司2022 年股权激励计划调整及首次授予事项之核查意见
Regulatory Filings
2022-06-07 Chinese
关于向激励对象授予股票期权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's 2022 stock option incentive plan, including the approval by the board and supervisory committee, the number of stock options granted, the exercise price, the vesting schedule, performance conditions, and legal and financial advisor opinions. It includes specifics about the stock option plan, the allocation to executives and employees, and the impact on financials. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is not a call transcript, nor a voting result announcement. It is a detailed disclosure about a capital-related incentive plan involving stock options granted to employees and executives, which falls under capital/financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2022-06-07 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.